Indication: Respiratory Syncytial Virus (RSV)

A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)

Sub-indication: Respiratory Syncytial Virus (RSV)

Drug Study

Principal Investigator: Tonya Robinson, M.D.
Norton Children's Neonatology, affiliated with the UofL School of Medicine

Sponsor: MedImmune, LLC

Search our entire site.